Michael Braun is a member of the New York corporate group which he headed for 10 years through 2011. He is also the co-chair of the Japan Practice Group. Mr. Braun is a transactional attorney whose practice focuses on U.S.-based transactional and advisory work, mostly on behalf of Asian and European companies, including many Japanese companies.
Mr. Braun represents some of Japan's largest companies in their U.S. transactions, including mergers & acquisitions, joint ventures,collaboration and other strategic alliances and corporate investments. He also works with other foreign-based and U.S. companies interested in securing strategic investments and alliances around the world. Mr. Braun's clients include global aerospace, retail, real estate, printing, food and beverages, and pharmaceutical/biotechnology businesses.
In the last five years, Mr. Braun assisted numerous Japanese companies in the pharmaceutical, life science and technology sectors in connection with their acquisitions in the U.S. of both private and public companies. He also has counseled them regarding numerous venture capital and private investments in emerging companies, focusing on drug delivery, medical devices, and medical diagnostic products as well as new pharmaceutical products.
In 2017, Mr. Braun was selected to the New York Metro Super Lawyers List for Business & Corporate Law. Mr. Braun is named “Dealmaker of the Week, May 20, 2010” in connection with representing Astellas Pharma in the tender offer for OSI, the first successful unsolicited tender offer by a Japanese company for a U.S. company. Legal 500 2011 cites a client saying Mr. Braun is “one of the best business lawyers we have worked with. He really knows our company, what is important to us and is a passionate advocate.”
Mr. Braun was born and raised in Tokyo, Japan and speaks fluent Japanese.Show More
Represented WM Partners, a private equity firm backed by Latin American investors that specializes in buyout investments in the health and wellness sectors, and its portfolio company Wellnext, in the purchase of substantially all of the assets of Natural Dynamics, LLC, a Texas-based nutraceutical company that holds leading nutraceutical brands including Natural Calm and Organic Life Vitamins, as well as the educational site Organic Connections.
Represented WM Partners, a private equity firm backed by Latin American investors that specializes in buyout investments in the health and wellness sectors, and its portfolio company Wellnext, in the purchase of all of the membership interest in Stop Aging Now, LLC, a Maryland-based nutraceutical company. In addition to Stop Aging Now, Wellnext also holds a number of nutritional supplement brands including Nature's Products, True Health, Blessed Herbs, and Nutri-Health Supplements.
Represented Dai Nippon Printing Co., Ltd., a major Japanese printing firm, in the acquisition of Foto Fantasy, Inc. (d/b/a Innovative Foto), a leading designer, manufacturer, operator and distributor of digital imaging photo kiosks in the United States, from an affiliate of Sankaty Advisors, an independently managed affiliate of Bain Capital.
Represented Olympus Corporation in the divestiture of its biotech business.
Represented Nihon Kohden Corporation in its acquisition of Defibtech, LLC, a US medical instruments company developing and manufacturing, among other things, state-of-the art defibrillators.
Represented Wacoal Corp., one of the largest women's intimate apparel makers globally, in the acquisition of Eveden Group, a UK company with subsidiaries and operations in more than 10 countries, for approximately $250 million.
Represented Astellas Pharma Inc., Japan's second largest pharmaceutical company, in its $4 billion acquisition of OSI Pharmaceuticals (NASDAQ: OSIP), the first successful unsolicited tender offer by a Japanese company in the U.S.
Represented Olympus Corporation in its acquisition of Stryker's interest in the OP-1 product family for use in orthopaedic bone applications.
Represented Rohm Co., Ltd., a Japanese maker of electronic and semi-conductor products in the acquisition of Kionix, Inc., a privately held company and one of the world’s leading suppliers of MEMS inertial sensors for over $233 million.
Represented Astellas Pharma in the formation of a joint venture, Perseid Therapeutics, with Maxygen, Inc. (NASDAQ: MAXY) that will assume all of the discovery, research and development of Maxygen’s existing protein therapeutics.
Represented Astellas Pharma in its offer to purchase all of the stock of CV Therapeutics (NASDAQ: CVTX) for over $1 billion.
Represented Astellas Pharma in its acquisition of Agensys, Inc., an oncology focused biotechnology company, for $537 million (cash $387 million, milestones $150 million).
Represented Astellas Pharma U.S., Inc., Astellas Pharma’s US subsidiary, in the acquisition of Dynogen Pharmaceuticals, Inc.’s North Carolina research facility specializing in genitourinary disorders.
Represented Dai Nippon Printing Co., Ltd., in the acquisition of Sony Chemicals & Information Services Corporation’s global assets constituting the thermal ribbon business.
Represented Astellas Pharma in the purchase of Comentis Inc.’s Series D Preferred Stock for $20 million in connection with a Collaboration Agreement with Comentis with a reported value of $780 million.
Represented Hantro Products Oy, a Finnish company in connection with an exchange offer valued at about $60 million with ON2 Technologies (AMEX: ONT), a leader in video compression software and solutions resulting in Hantro owing 12% of On2 Technologies.
Represented Dai Nippon Printing in the initial purchase of a majority interest, and subsequent purchase pursuant to a consent solicitation of the balance of the stock of Pixel Magic Imaging, a leader in digital imaging solutions and photo kiosks.
Represented Astellas US LLC in the acquisition of the worldwide rights to AMEVIVE® from Biogen Idec Inc. (NASDAQ: BIIB).
Represented Daiwa America Corporation in a business alliance agreement with, and its $52 million purchase of common stock of Sagent Advisors, Inc., a private M&A investment banking boutique firm.
Represented Daiichi Pharmaceutical Co., Ltd. and Sankyo Pharmaceutical Co., Ltd. in connection with their merger creating Daiichi-Sankyo Pharmaceutical Co., Ltd.
Represented Fujisawa Pharmaceutical Co., Ltd. And Yamanouchi Pharmaceutical Co., Ltd. With respect to U.S. and international issues in connection with their $7.6 billion merger creating Astellas Pharma Inc. and the Astellas group of companies.
Represented Dai Nippon Printing Co., Ltd.’s investments in Palo Alto Research Center; Panacea Pharma; Cangen Biotechnologies; Acucela Inc. and Molecular Imprints.